Overview

There should be, and in the best of cases there is, a synergy between basic research and patient care. However, this synergy is hard to develop because the techniques required to be a successful researcher are so different from the skills required to be an outstanding physician. Harold R. Roberts, M.D., of the University of North Carolina at Chapel Hill, is an example of a physician-researcher who has benefited from having his feet in both the world of patient care and the world of the laboratory: he has let clinical problems direct his basic research effort and conversely has adopted research advances in his care of patients. Dr. Roberts's long and continuing career has included many research and clinical advances. He was part of the first group to determine the amino acid sequence of the important thrombin inhibitor hirudin and part of the group that prepared the first cryoprecipitates which were the first alternative to plasma as therapy in hemophilia A. Dr. Roberts has made significant advances in understanding the protein chemistry behind hemophilia B; he was among the first researchers to identify some patients as not being completely deficient but instead as having measurable levels of protein and subsequently demonstrated that this protein was dysfunctional. This important advance led him to a classification scheme for patients into Cross Reacting Material (CRM) positive, negative, and reduced. Dr.

Full Product Details

Author:   Dougald M. Monroe ,  Ulla Hedner ,  Maureane R. Hoffman ,  Claude Negrier
Publisher:   Springer-Verlag New York Inc.
Imprint:   Springer-Verlag New York Inc.
Edition:   Softcover reprint of the original 1st ed. 2001
Volume:   489
Dimensions:   Width: 17.80cm , Height: 1.00cm , Length: 25.40cm
Weight:   0.390kg
ISBN:  

9781461354741

ISBN 10:   1461354749
Pages:   182
Publication Date:   24 September 2012
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

I. Infectious Disease Risk.- 1. The Transfusion-Transmitted Viruses in Blood Transfusion.- II. Unexplained Aspects of Hemophilia and Hemostasis.- 2. Are Patients with Glanzmann Thrombasthenia and the Bernard-Soulier Syndrome Protected Against Atherosclerosis?.- 3. Factor V: Dr. Jeckyll and Mr. Hyde.- III. Novel Approaches to Therapy.- 4. Gene Therapy for Hemophilia B: AA V-Mediated Transfer of the Gene for Coagulation Factor IX to Human Muscle.- 5. Use of Prophylaxis to Prevent Complications of Hemophilia.- 6. Factor VIII Inhibitors.- 7. Use of High Dose Factor VIIa in Hemophilia Patients.- IV. Inhibitor Development in Hemophilia Patients.- 8. The Incidence of Inhibitors in Hemophilia A and the Induction of Immune Tolerance.- 9. Mechanisms of B-Cell Tolerance.- 10. Mechanisms of Unresponsiveness: T- and B-Cell Mediated Mechanisms of Anergy.- 11. CD4+ T Cells Specific for Factor VIII as a Target for Specific Suppression of Inhibitor Production.- 12. CD40L Pathway Blockade as an Approach to Immuno-therapy.- Abstracts.- Contributors.

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions